Recent studies of humanmonoclonallupus autoantibodies have revealed that someof them are crossreactive with platelets. To clarify further the bivalendes in anti-DNA and anti-platelet autoantibodies, we established nine human B cell lines producing monoclonal anti-platelet antibodies from patients with idiopathic thrombocytopenic purpura by Epstein-Barr virus transformation and studied the DNA-binding properties of these antibodies. Three of the antibodies showed cross-reactivity with single-stranded DNA(SSDNA),as determined by enzyme-linked immunosorbent assay and one of them was also found to bind to the synthetic polynucleotides; poly (dT) and poly (I), as well as to SSDNA.These findings suggest that cross-reaction between anti-DNAand anti-platelet antibodies is based on overlaps in specificity existing as commonpart of both autoantibodies.
denatured DNA(dDNA), are known to react with platelets (1, 2) . The platelet-binding properties of monoclonal anti-DNA autoantibodies are considered to be clinically significant, because thrombocytopenia is often seen in patients with systemic lupus erythematosus (SLE) (3, 4) . For adequate evaluation of the bivalencies in anti-DNA and anti-platelet autoantibodies, however, studies on DNA-binding properties of monoclonal anti-platelet antibodies are also required.
Therefore, we established humanB cell lines producing monoclonal anti-platelet antibodies from patients with idiopathic thrombocytopenic purpura (ITP) by Epstein-Barr virus (EBV) transformation and then tested the DNA-binding properties of these antibodies for this study.
In the present paper, we report human monoclonal anti-platelet antibodies cross-reactive with DNAin order to reach a better understanding of the overlapping specificity of these autoantib odies.
MATERIALS AND METHODS
Isolation of lymphocytes
Lymphocytes were obtained from three antiDNAseronegative patients with ITP with their consent. Mononuclear cells from heparinized peripheral blood from one patient were purified by gradient centrifugation over Ficoll-Conray. Spleen cells from two patients were obtained at the time of splenectomy. The spleens were cut into small pieces followed by passage through a screen in RPMI1640 (Gibco Laboratories, Grand Island, NY) containing buffer, pH 4.5) was added to each well and the plates were incubated at 22°C for 20 minutes before determining the optical density at 492 nm for each well in a Titertek Multiskan MC(Flow).
Measurement of anti-DNA antibodies
For the preparation of single-stranded DNA (SSDNA), calf thymus DNA (Sigma Chemical Co., St. Louis, MO) was dissolved in PBS and denatured by heating at 100°C for 10 minutes followed by rapid cooling in ice-water. Double-stranded DNA (dsDNA) was isolated from peripheral white blood cells according to the method originally described by Blin and Stafford with slight modification (6) . A 50-[x\ aliquot of each of these DNAsolutions (2.5 g/ml) was added to the wells of poly-L-lysinetreated polystyrene microtiter plates and the plates were dried at 37°C for 18 hours. The plates were washed three times with PBS-Tween20 and then blocked with egg albumin buffer as the plateletcoated plates. One hundred microliters of culture supernatant was added and each plate was incubated at 37°C for 1 hour. The remainder of the assay was carried out as for the measurement of anti-platelet antibodies.
In all assays, plates without antigens served as controls. Table 1 shows the reactivities of these monoclonal antibodies with platelet and SSDNA,as determined by ELISA. They reacted with platelet to different degrees and three of them, Nos. 3, 5 and 8, also reacted with SSDNA. None of these monoclonal antibodies bound to plates without antigens, nor did culture medium show any reactivity with these antigen-coated plates.
2. Cross-reactive specificities of humanmonoclonal anti-platelet an tibodies The specificities of three monoclonal anti-platelet antibodies cross-reactive with SSDNA were determined using direct-binding ELISA (Table 2) . These monoclonal antibodies bound to SSDNA,but not to dsDNA.
Moreover, the binding specificity of antibody No. dsDNA: double-stranded DNA * Values represent optical densities read at 492 nm in ELISA.
8, that most strongly reactive with SSDNA, was determined by competitive inhibition assay (Fig. 1) . This monoclonal antibody bound to the synthetic polynucleotides; poly(dT) and poly(I), as well as to SSDNA, but not to dsDNA, RNA, poly(dA), poly(C), poly(G), poly(U) or cardiolipin. The binding of antibody No. 8 to platelet was also inhibited by SSDNA, poly(dT) and poly(I) with the same pattern as that shown in Fig. 1 (data not  shown) . Conversely, the reactivity of this monoclonal antibody with SSDNAwas also inhibited by glutaraldehyde-fixed platelets (Fig. 2) 50^g/ml reduced the binding ability of antibody No. 8 to them by almost 90%. On the other hand, the treatment of platelet-coated plates with DNAaseI even at a concentration of 5 mg/ml had no effect on the binding of this monoclonal antibody (Fig. 3) . Wetherefore concluded that this cross-reactivity was not due to the presence of DNAitself bound to the surface of platelets. because thrombocytopenia is often seen in patients with SLE (3, 4) . Moreover, Rauch et al found that anti-platelet activity was strongly correlated with anti-dDNA reactivity (2) . These reported clones have been screened and selected for anti-dDNAactivity and then tested for binding to platelets. In order to clarify further the bivalencies in anti-DNA and antiplatelet autoantibodies, we conversely studied the DNA-binding properties of the EBV-transformed human B cell clones screened and selected for antiplatelet activity. Our results indicated that some of these anti-platelet antibodies were cross-reactive with
DNAand that moreover, one of them, No. 8, was also able to react with multiple synthetic polynucleotides of different base composition; some of the monoclonal anti-DNA autoantibodies produced by human-human hybridomas (7) or EBVtransformation (8) also have multiple binding reactions of this type. Taken together, these findings suggest that cross-reaction between anti-DNA and anti-platelet antibodies is based on overlaps in specificity existing as commonpart of both autoantibodies.
recognized by antibody No. 8 was not DNAitself bound to the surface of platelets, though DNA receptors have been described on humanplatelets (9) . Moreover, as this antibody showed base-specific preference in the competitive inhibition assay, we believe that the common structural properties of negatively charged arrays in the phosphodiester ribose backbone of DNAdo not play a major role in this cross-reaction with platelets. Accordingly, there must be particular epitopes shared by both platelets and DNA,even though they appear to be structurally distinct (1 0). A monoclonal anti-platelet antibody produced by a hybridoma derived from a mouse immunized with platelets has also been shown to bind to HI histones of cell nuclei (ll) . Thus, it is suggested that the structures for antigen recognition by anti-platelet autoantibodies are widely distributed and the immunogenic stimulus for their production are more complex.
At present, we are unable to commenton whether our monoclonalanti-platelet antibodies obtained from patients with ITP are responsible for the pathogenesis of thrombocytopenia in these patients. Studies on idiotypic analysis of these monoclonal anti-platelet antibodies and serum autoantibodies in ITP would provide useful information for this problem. In fact, using the same EBVtransformation method, Sasaki et al. have succeeded in establishing the monoclonal anti-DNA producing cell lines expressing the cross-reactive idiotypes of anti-DNA autoantibodies in SLE sera (12, 13) . Furthermore, it is nowaccepted that anti-platelet autoantibodies of the IgM class, like our present monoclonal antibodies, are as significant as those of the IgG class when considering the pathogenesis of platelet destruction in ITP (14, 15 ). Therefore we think that studies on autoimmunedisease using monoclonal antibodies is useful for simplifying the complex autoantibody-antigen interactions occurring in this type of condition. Weshowed that overlapping specificity existed as commonpart of anti-DNA and anti-platelet antibodies. However, the precise role of bivalencies in anti-DNA and anti-platelet autoantibodies in creating the common clinical manifestations seen in SLE and ITP (16, 17) remains to be determined. For the solution of this problem, it will be important to knowwhether or not the platelet antigens responsible for anti-platelet autoantibodies in ITP are similar to those in SLE.
